Sotera Health Co (SHC)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $4.74B
Last updated: Nov 17, 2026 at 11:06 AM ET
Sotera Health Co (SHC) P/E Ratio & Valuation History
Sotera Health (SHC) trades at 17.1x trailing earnings and 3.8x sales. Its P/E of 17.1x is below its 5-year median of 18.9x. Its forward P/E is 16.1x. The median P/E across 8 similar companies is 33.8x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 6.2% higher over the next year. Its free cash flow yield is 2.9%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 17.1x |
| Forward P/E | 16.1x |
| Price to sales | 3.8x |
| Price to book | 6.3x |
| EV/EBITDA | 11.8x |
| Price to FCF | 34.3x |
| EV/FCF | 48.0x |
| PEG | 1.7 |
| FCF yield | 2.9% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 17.1x | 18.9x | N/A |
| P/S | 3.8x | 4.0x | N/A |
| P/B | 6.3x | 8.7x | N/A |
Valuation History
Over the 6 year ends shown, its P/E ranged from 8.6x in 2022 to 227.0x in 2020.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $17.64 | 20.5x | 4.3x | 8.3x |
| 2024 | $13.68 | 19.5x | 3.5x | 9.6x |
| 2023 | $16.85 | 20.8x | 4.5x | 10.8x |
| 2022 | $8.33 | 8.6x | N/A | 6.7x |
| 2021 | $23.55 | 26.8x | 7.1x | 11.2x |
| 2020 | $27.44 | 227.0x | 8.6x | 15.4x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About SHC
What is SHC's forward P/E ratio?
Sotera Health has a forward P/E ratio of 16.1x.
Is SHC stock overvalued?
GNG's valuation label for SHC is Undervalued. Its P/E of 17.1x compares with a median of 33.8x across 8 similar companies.
What is SHC's price to sales ratio?
Sotera Health has a price to sales ratio of 3.8x.
What is Sotera Health's average P/E ratio over 5 years?
Sotera Health's median P/E over the last 5 years is 18.9x, from 60 month-end values through Oct 2026.
What is SHC's PEG ratio?
Sotera Health has a PEG ratio of 1.7.
SHC pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors